Needham & Company Upgrades Hologic (HOLX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches up on megacap strength; Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar rises to session high after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- BioNTech ends colorectal cancer mRNA therapy trial early
Leerink Partners Remains Bullish on Hologic (HOLX) as Lower Tax Rate Helps Drive 1Q Results
January 28, 2016 9:31 AM ESTLeerink Partners maintained an Outperform rating on Hologic (NASDAQ: HOLX), and cut the price target to $44.00 (from $47.00), following the company's 1Q earnings report. HOLX reported revenue of $695M, which was $6M ahead of the Street's estimate, with outperformance primarily from GYN and... More
Hologic (HOLX) Tops Q1 EPS by 4c; Guides FY EPS Higher
January 27, 2016 4:07 PM ESTHologic (NASDAQ: HOLX) reported Q1 EPS of $0.46, $0.04 better than the analyst estimate of $0.42. Revenue for the quarter came in at $695.2 million versus the consensus estimate of $688.04 million.
GUIDANCE:
Hologic sees Q2 2016 EPS of $0.45-$0.46, versus the consensus of $0.45. Hologic sees Q2... More
